Recommendations for RSV prophylaxis in children with congenital heart defects. Consensus paper of the Working Group for Pediatric Cardiology of the Austrian Society of Pediatric and Adolescent Medicine, 2004;Empfehlungen zur RSV-prophylaxe bei kindern mit angeborenem herzfehler. Konsensuspapier der Arbeitsgruppe für Kinderkardiologie der Österreichischen Gesellschaft für Kinder- und Jugendheilkunde, 2004

Monatsschrift fur Kinderheilkunde

Volumn 153, Issue 9, 2005, Pages 878-880

  Pinter, M ^a   Geiger, R ^b  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Congenital heart disease (CHD); Palivizumab; Pediatric cardiology; RSV ("respiratory syncytial virus") prophylaxis; Synagis

Indexed keywords

PALIVIZUMAB;

CARDIOLOGY; CHILD; CONFERENCE PAPER; CONGENITAL HEART MALFORMATION; HUMAN; INFECTION CONTROL; MEDICAL LITERATURE; PEDIATRICS; PRACTICE GUIDELINE; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

EID: 24944433140     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-005-1197-z     Document Type: Conference Paper

References (10)

1. AAP Policy Statement American Academy of Pediatrics (2003) Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics 112:1442-1446
2. Altman CA, Englund JA, Demmler G (2000) Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 21:433-438
3. Boigner H, Trittenwein G, Marx M et al. (1999) Pulmonary failure after Norwood procedure: indication for extracorporeal membrane oxygenation? A case report. Artif Organs 23:1036-1037
4. Deutsche Gesellschaft für Pädiatrische Kardiologie (2004) Stellungnahme der Deutschen Gesellschaft für Pädiatrische Kardiologie zur RSV-Prophylaxe mit Palivizumab (Synagis). Monatsschr Kinderheilkd 152: 222-223
5. Feltes TF, Cabalka AK, Meissner HC et al. (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143:532-540
6. Khongphatthanayothin A, Wong PC, Samara Y (1999) Impact of respiratory syncytial virus infection on surgery for congenital heart disease: post-operative course and outcome. Crit Care Med 27:1974-1981
7. MacDonald NE, Hall CB, Suffin SC et al. (1982) Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 307:397-400
8. Moler FW, Khan AS, Meliones JN et al. (1992) Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 20:1406-1413
9. Resch B, Berger A, Urlesberger B et al. (2004) Konsensuspapier der Arbeitsgruppe Neonatologie und pädiatrische Intensivmedizin der österreichischen Gesellschaft für Kinder- und Jugendheilkunde; Empfehlungen zur Respiratory Syncytial Virus-Prophylaxe bei Frühgeborenen mit Palivizumab-Update 2003. Monatsschr Kinderheilkd 2:223-224
10. Tulloth R, Marsh M, Blackburn M (2003) Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 13:420-423